Cosmo spinout Cassiopea wins FDA approval for new acne drug
A small Swiss-listed biotech spinout secured FDA approval for their first drug, setting them up to compete in a crowded market for acne.
Cassiopea received an okay for Winlevi, the drug that has been at the top of the company’s pipeline since the company spun out from the Swiss pharma Cosmo in 2015. It will take a little bit longer to market, though, likely because the company has little commercial infrastructure so far. The biotech said they plan to start early 2021. A price will be announced in Q4, Reuters reported.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.